X4 Pharmaceuticals, Inc. (XFOR) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 12 Buy, 1 Hold.
The consensus price target is $10.00, representing an upside of 138.1% from the current price $4.20.
Analysts estimate Earnings Per Share (EPS) of $-3.90 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.19 vs est $-3.90 (beat +95.2%). 2025: actual $-1.87 vs est $-2.04 (beat +8.2%). Analyst accuracy: 0%.
XFOR Stock — 12-Month Price Forecast
$10.00
▲ +138.10% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for X4 Pharmaceuticals, Inc., the price target is $10.00.
The average price target represents a +138.10% change from the last price of $4.20.
XFOR Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to X4 Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — XFOR
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.19
vs Est –$3.90
▲ 1,996.8% off
2025
Actual –$1.87
vs Est –$2.04
▲ 9.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — XFOR
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.002B
▲ 14.0% off
2025
Actual $0.035B
vs Est $0.034B
▲ 2.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
